CHRS Coherus BioSciences Inc.

12.85
+0.15  (1%)
Previous Close 12.70
Open 12.80
Price To book 20.40
Market Cap 659965553
Shares 51,359,187
Volume 283,119
Short Ratio 10.39
Av. Daily Volume 504,977

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released January 2016. Endpoints met. However, commercialization not possible in US before 2029 due to patent issues
CHS-0214
Rheumatoid arthritis
Phase 2b data released June 2016
CHS-131
Relapsing remitting multiple sclerosis (RRMS)
Phase 3 trial met endpoint November 2015. However, commercialization not possible in US before 2029 due to patent issues
CHS-0214
Psoriasis
Phase 3 top-line data met endpoints August 2016. Full data due released January 10, 2016. BLA filing due towards the end of 2Q 2017.
CHS-1420
Psoriasis
CRL announced June 12, 2017. BLA to be resubmitted end of 2017.
CHS-1701
Pegfilgrastim biosimilar

Latest News

  1. 3 Stocks With McDonald's-Like Return Potential
  2. Coherus BioSciences, Inc. breached its 50 day moving average in a Bearish Manner : CHRS-US : September 11, 2017
  3. AbbVie Scores 2 Wins: 1 Threatens Regeneron
  4. Coherus BioSciences Provides Update on ‘619 IPR Institution Decision
  5. Coherus BioSciences Management to Present at Three Investor Healthcare Conferences in September
  6. Coherus BioSciences Announces Positive Topline Results for Clinical Pharmacokinetic Bioequivalence Study for CHS-1420 (Humira® Biosimilar Candidate) versus European Marketed Humira in Healthy Subjects
  7. See what the IHS Markit Score report has to say about Coherus BioSciences Inc.
  8. Coherus BioSciences, Inc. breached its 50 day moving average in a Bullish Manner : CHRS-US : August 23, 2017
  9. Coherus Bio Jumps on Private Placement
  10. Coherus Secures Private Placement from Temasek
  11. Edited Transcript of CHRS earnings conference call or presentation 8-May-17 8:30pm GMT
  12. Here's Why Coherus Biosciences Rose as Much as 22.2% Today
  13. Coherus BioSciences reports 2Q loss
  14. Coherus BioSciences Reports Second Quarter 2017 Corporate Highlights and Financial Results
  15. Investor Network: Coherus BioSciences, Inc. to Host Earnings Call
  16. Coherus BioSciences Files Petition for Inter Partes Review of ENBREL® Patent 8,163,522
  17. Coherus BioSciences to Report Second Quarter 2017 Financial Results on August 7th

SEC Filings

  1. 8-K - Current report 171074220
  2. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 171069838
  3. SC 13G - Statement of acquisition of beneficial ownership by individuals 171063513
  4. 8-K - Current report 171057979
  5. 8-K - Current report 171045202
  6. CT ORDER - Confidential treatment order 171044150
  7. 8-K - Current report 171025059
  8. SC 13G - Statement of acquisition of beneficial ownership by individuals 171020142
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 171011863
  10. 8-K - Current report 171011539